NCT03661346View on ClinicalTrials.gov

Esmolol vs. Labetalol in Endoscopic Sinus Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

March 30, 2018

Study Completion Date

March 30, 2018

Conditions
Chronic Sinusitis
Interventions
DRUG

Labetalol

"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"

DRUG

Esmolol

"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"

Trial Locations (1)

77550

University of Texas Medical Branch, Galveston

All Listed Sponsors
lead

The University of Texas Medical Branch, Galveston

OTHER

NCT03661346 - Esmolol vs. Labetalol in Endoscopic Sinus Surgery | Biotech Hunter | Biotech Hunter